TELA Bio Awarded Synthetic Bioabsorbable Mesh Products Agreement with Premier, Inc.
20 July 2022 - 9:00PM
TELA Bio, Inc. (“TELA”), a commercial-stage medical technology
company focused on providing innovative soft-tissue reconstruction
solutions that optimize clinical outcomes by prioritizing the
preservation and restoration of the patient’s own anatomy, today
announced that it has been awarded a group purchasing agreement for
Synthetic Bioabsorbable Mesh Products with Premier, Inc. Effective
October 1st, 2022, the new agreement allows Premier members, at
their discretion, to take advantage of special pricing and terms
pre-negotiated by Premier for OviTex® and OviTex PRS Reinforced
Tissue Matrix.
Premier (NASDAQ: PINC) is a leading healthcare
improvement company, uniting an alliance of approximately 4,400
U.S. hospitals and 225,000 other providers and organizations to
transform healthcare. With integrated data and analytics,
collaboratives, supply chain solutions, and consulting and other
services, Premier enables better care and outcomes at a lower
cost.
“We are both grateful and honored to be awarded
this important agreement,” said Antony Koblish, President and CEO
of TELA Bio. “This is a significant opportunity for our company,
and we look forward to working with Premier members to provide
their surgeons and patients with access to our advanced soft-tissue
repair portfolio.”
OviTex and OviTex PRS Reinforced Tissue Matrix are
a next generation soft tissue repair platform for use in general,
plastic and reconstructive surgery. OviTex utilizes layers of
naturally sourced tissue interwoven with permanent or resorbable
polymer suture to facilitate tissue remodeling, optimize strength,
and minimize permanent synthetic foreign body footprint. To learn
more, please visit www.telabio.com/ovitex.html.
About TELA Bio, Inc.TELA Bio, Inc.
(NASDAQ: TELA) is a commercial-stage medical technology company
focused on providing innovative technologies that optimize clinical
outcomes by prioritizing the preservation and restoration of the
patient's own anatomy. The Company is committed to providing
surgeons with advanced, economically effective soft-tissue
reconstruction solutions that leverage the patient's natural
healing response while minimizing long-term exposure to permanent
synthetic materials. For more information, visit
www.telabio.com.
Caution Regarding Forward-Looking
Statements
This press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations are forward-looking statements and reflect the current
beliefs of TELA's management. These statements are not guarantees
of future performance and are subject to certain risks,
uncertainties and other factors that could cause actual results and
events to differ materially and adversely from those indicated by
such forward-looking statements. These risks and uncertainties are
described more fully in the "Risk Factors" section and elsewhere in
our filings with the Securities and Exchange Commission and
available at www.sec.gov, including in our Annual Report on Form
10-K and Quarterly Reports on Form 10-Q. Any forward-looking
statements that we make in this announcement speak only as of the
date of this press release, and TELA assumes no obligation to
update forward-looking statements whether as a result of new
information, future events or otherwise after the date of this
press release, except as required under applicable law.
CONTACT:
TELA Bio ContactGreg FirestoneVice
President, Strategic Customer
Relations224-612-0792gfirestone@telabio.com
Media ContactAlyson
Kuritz908-892-7149alyson@0to5.com
Investor ContactGreg
Chodaczek332-895-3230ir@telabio.com
Premier (NASDAQ:PINC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Premier (NASDAQ:PINC)
Historical Stock Chart
From Jul 2023 to Jul 2024